NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Linda Powers, NW Bio’s CEO commented, “We believe that our DCVax platform technologies are potentially applicable to all types of solid tumor cancers, which comprise the vast majority of all cancers. We are working to build the infrastructure and systems that can enable the scale-up of production to such volumes – and can do so at a price level that will be affordable for widespread use of DCVax treatments.”

“The phased buildout of our Sawston, UK facility and now our acquisition of Flaskworks are major building blocks towards achieving these goals. These steps, along with others in process, have been years in the making to reach fruition at the same time as we are reaching the results of our Phase 3 clinical trial of DCVax-L for Glioblastoma.

From Wednesday, 6 July 2022 + 90 MHRA working days.
Excluding Weekends and public holidays
in United Kingdom – Nationwide. Change Country / Change Constituent Country
Result: Wednesday, 9 November 2022
126 calendar days – 36 days skipped:
Excluded 18 Saturdays
Excluded 18 Sundays

SNO abstracts released: Friday November 11, 2022